新型前哨淋巴结示踪剂的制备及动物实验研究

doi:10.3969/j.issn.1007-3969.2016.03.007

中国癌症杂志 ›› 2016, Vol. 26 ›› Issue (3): 245-250.doi: 10.3969/j.issn.1007-3969.2016.03.007

新型前哨淋巴结示踪剂的制备及动物实验研究

丛斌斌^1,2，孙　晓²，宋现让³，曹晓珊^1,2，刘雁冰²，赵　桐²，田崇麟^1,2，于金明⁴，王永胜²

1. 济南大学山东省医学科学院医学与生命科学学院，山东济南 250200 ；
2. 山东大学附属山东省肿瘤医院乳腺病中心，山东济南 250117 ；
3. 山东大学附属山东省肿瘤医院基础实验室，山东济南 250117 ；
4. 山东大学附属山东省肿瘤医院放疗科，山东济南 250117

出版日期:2016-03-30 发布日期:2016-06-13
通信作者: 王永胜　E-mail:wangysh2008@aliyun.com
基金资助:
山东省自然科学基金重点项目(ZR2014HZ003)。

The preparation and experimental study of a new sentinel lymph node tracer

CONG Binbin^1,2, SUN Xiao², SONG Xianrang³, CAO Xiaoshan^1,2, LIU Yanbing², ZHAO Tong¹, TIAN Chonglin^1,2, YU Jinming⁴, WANG Yongsheng²

1.School of Medicine and Life Sciences, University of Jinan and Shandong Academy of Medical Sciences, Jinan 250200, Shandong Province, China; 2.Breast Cancer Center, Shandong Cancer Hospital Affiliated to Shandong University, Jinan 250117, Shandong Province, China; 3.Basic Laboratory, Shandong Cancer Hospital Affiliated to Shandong University, Jinan 250117, Shandong Province, China; 4.Radiotherapy Department, Shandong Cancer Hospital Affiliated to Shandong University, Jinan 250117, Shandong Province, China

Published:2016-03-30 Online:2016-06-13
Contact: WANG Yongsheng E-mail: wangysh2008@aliyun.com

摘要/Abstract

摘要： 背景与目的：前哨淋巴结活检是临床腋窝淋巴结阴性早期乳腺癌患者治疗的标准。准确定位前哨淋巴结对分期、预后及治疗至关重要。该研究将利妥昔单抗与荧光示踪剂吲哚菁绿偶联，制备新型前哨淋巴结示踪剂，确定最佳偶联比例，并对其生物学特性、安全限度及定位性能进行研究。方法：直接偶联法制备新型前哨淋巴结吲哚菁绿-利妥昔单抗，双层析快速薄层层析-硅胶层析纸法测定标记率，非还原型SDS聚丙烯酰胺凝胶电泳法和双抗体夹心间接酶联免疫测定法检测新型示踪剂中单抗分子完整性和免疫活性，按中华药典要求检测新型示踪剂的安全限度及在小鼠体内前哨淋巴结的定位性能。结果：新型示踪剂中利妥昔单抗分子完整且保持了单抗的免疫活性，利妥昔单抗大分子上吲哚菁绿的标记率为100%，新型示踪剂为无菌、无致热原的溶液且局部注射不会产生危害。利妥昔单抗与吲哚菁绿质量比例为4∶1、6∶1偶联形成的新型示踪剂，前哨淋巴结显像效果最佳。前哨淋巴结定位与核素法一致。结论：吲哚菁绿-利妥昔单抗偶联的新型前哨淋巴结示踪剂的制备工艺简单且无放射性危害，其中单抗的分子完整性和免疫活性无破坏，为无菌、无致热原、无急性毒性的示踪剂，能够用于前哨淋巴结显像。

关键词: 前哨淋巴结, 显像剂, 利妥昔单抗, 吲哚菁绿, 淋巴显像

Abstract: Background and purpose: Sentinel lymph node biopsy is regarded as the standard of care in patients without clinical axillary lymph node metastases in early-stage breast cancer. Accurate detection of sentinel lymph node is an important step for staging, prognosis, and treatment. In this study, a new sentinel lymph node tracer was produced by the rituximab to combine with the fluorescence tracer (indocyanine green, ICG), and to identify the most appropriate combination ratio of the two agents. Its biological property and safety limitation were evaluated. Methods: Rituximab was combined directly with ICG. The new tracer was analyzed for labeled rate by instant thin-layer chroma-tography-silica gel, molecular integrity by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and molecular immune activity by ELLAS. The safety limitation was tested according to the Chinese Pharmacopeia. The localization ability of sentinel lymph node was tested in mice. Results: The new tracer was intact and kept the immune activity of rituximab. The ICG labeled rate of rituximab was 100%. The new tracer was bacteria and pyogen free, and was safe to body with location injection. The most appropriate combination ratio of rituximab and ICG was 4∶1 and 6∶1 with the best sentinel lymph node imaging. The location of sentinel lymph node identified by the new tracer was accorded with the radiotracer. Conclusion: The preparation method of the new sentinel lymph node tracer is simple and no radioactive injury. The new tracer has no bacteria, no pyogen and no acute toxicity, and can be used in sentinel lymph node visualization.

Key words: Sentinel lymph node, Imaging agent, Rituximab, Indocyanine green, Lymphoscintigraphy

丛斌斌,孙　晓,宋现让,等. 新型前哨淋巴结示踪剂的制备及动物实验研究[J]. 中国癌症杂志, 2016, 26(3): 245-250.

CONG Binbin, SUN Xiao, SONG Xianrang, et al. The preparation and experimental study of a new sentinel lymph node tracer[J]. China Oncology, 2016, 26(3): 245-250.

[1]	赵家贤, 王春建, 丛斌斌, 王永胜 . 乳腺癌前哨淋巴结活检光声示踪剂的进展与展望[J]. 中国癌症杂志, 2021, 31(10): 873-878.
[2]	鲁圆圆, 杨　帆, 郑　莹. 子宫内膜癌前哨淋巴结应用的研究进展与展望[J]. 中国癌症杂志, 2021, 31(10): 944-948.
[3]	李　培, 陈嘉健, 吴　炅. 乳腺癌前哨淋巴结的研究热点与评价[J]. 中国癌症杂志, 2020, 30(3): 161-165.
[4]	郭　瑢, 李　伦, 张　琪, 修秉虬, 杨犇龙, 王　嘉, 苏永辉, 季玮儒, 张莹莹, 邵志敏, 吴　炅 . 中国乳腺癌前哨淋巴结活检现状调查研究[J]. 中国癌症杂志, 2020, 30(3): 166-173.
[5]	吴　爽 , 孙　晓 , 丛斌斌 , 毕　钊 , 周鹏鹏 , 石志强 , 王永胜 . 新型荧光示踪剂在乳腺癌前哨淋巴结活检术中的应用研究[J]. 中国癌症杂志, 2020, 30(3): 174-178.
[6]	丛斌斌 , 刘治国 , 孙　晓 , 曹晓珊 , 邱鹏飞 , 王春建 , 张朝蓬 , 田崇麟 , 吴　爽 , 王永胜 . 新型荧光靶向前哨淋巴结示踪剂的验证研究[J]. 中国癌症杂志, 2020, 30(3): 179-185.
[7]	吴爽,孙晓,丛斌斌,王永胜 . 乳腺癌前哨淋巴结活检示踪剂研究进展[J]. 中国癌症杂志, 2019, 29(7): 540-544.
[8]	郑卫真，孙菊杰，刘雁冰，邱鹏飞，毕　钊，赵　桐，王永胜. 乳腺癌新辅助化疗后腋窝淋巴结病理学完全缓解预测模型的验证与改良研究[J]. 中国癌症杂志, 2019, 29(6): 445-451.
[9]	毕钊，刘静静，陈鹏，刘雁冰，赵桐，孙晓，邱鹏飞，王永胜. 乳腺癌新辅助化疗后内乳区前哨淋巴结活检研究[J]. 中国癌症杂志, 2019, 29(2): 131-135.
[10]	丛斌斌,曹晓珊,于金明,等. 早期乳腺癌前哨淋巴结活检的前沿进展[J]. 中国癌症杂志, 2018, 28(3): 236-240.
[11]	石志强,邱鹏飞,丛斌斌,等. 临床淋巴结阴性乳腺癌新辅助化疗与腋窝降阶梯处理的研究[J]. 中国癌症杂志, 2018, 28(12): 922-927.
[12]	徐　宇,朱蕙燕,陈　勇,等. 前哨淋巴结活检在中国皮肤和肢端恶性黑色素瘤患者诊治中的临床意义[J]. 中国癌症杂志, 2018, 28(11): 819-826.
[13]	张　燕,孙　晓,赵　桐,等. 术中快速预测乳腺癌非前哨淋巴结转移模型的建立与验证研究[J]. 中国癌症杂志, 2017, 27(5): 368-375.
[14]	谭红娜,王攀鸽,刘　洋,等. MR间质淋巴造影在VX2兔乳腺癌内乳前哨淋巴结显像中的初步研究[J]. 中国癌症杂志, 2017, 27(12): 928-934.
[15]	田崇麟,孙　晓,刘雁冰,等. 乳腺癌前哨淋巴结活检术新型示踪剂的动物模型研究[J]. 中国癌症杂志, 2016, 26(7): 569-573.

新型前哨淋巴结示踪剂的制备及动物实验研究

The preparation and experimental study of a new sentinel lymph node tracer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价